drugset / Trial / NCT00152542

Follow-up at School-age of Children Who Participated in the Efficacy Study of Nitric Oxide for Premature Infants

NCT00152542

Phase 3 Completed 160 enrolled University of Chicago Mallinckrodt · collab
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Our previous data demonstrated that premature infants treated with inhaled nitric oxide at birth had improved neurodevelopmental outcomes at two years corrected age. We now wish to determine whether this benefit continues through school age.

Timeline

Start
2005-05
Primary completion
2006-09
Completion
2006-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Nitric Oxide Other / unclassified 5 ppm Inhaled